N-(3-氨基-1-甲基丙基)-N,N-二甲胺 | 60978-33-8

• 物质功能分类: 有机原料 - 氨基化合物
• 分子结构分类: 有机化合物 - 有机氮化合物
• 中文名称: N-(3-氨基-1-甲基丙基)-N,N-二甲胺
• 中文别名: (3-氨基-1-甲基丙基)二甲基胺
• 英文名称: 1-Amino-3-dimethylaminobutan
• 英文别名: 1,N¹,N¹-trimethyl-propanediyldiamine；1,N¹,N¹-Trimethyl-propandiyldiamin；N-(3-amino-1-methylpropyl)-N,N-dimethylamine；3-N,3-N-dimethylbutane-1,3-diamine
• CAS: 60978-33-8
• 化学式: C₆H₁₆N₂
• mdl: MFCD09864510
• 分子量: 116.206
• InChiKey: HMNAAVUZNWPXDC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.1
• 重原子数：
  8
• 可旋转键数：
  3
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  29.3
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 危险等级：
  IRRITANT
• 海关编码：
  2921290000
• WGK Germany：
  3

反应信息

• 作为反应物：
  描述：

  N-(3-氨基-1-甲基丙基)-N,N-二甲胺 、 2,7-bis(4-formylphenyl)-4-phenyl-7H-pyrrolo[2,3-d]pyrimidine 以 乙醇 为溶剂， 反应 5.0h， 以98%的产率得到2,7-bis{4-[(4-dimethylaminobutyl)iminomethyl]phenyl}-4-phenyl-7H-pyrrolo[2,3-d]pyrimidine
  参考文献：
  名称：

  [EN] 6-6 OR 5-6 FUSED BICYCLIC COMPOUNDS COMPRISING A PYRI(MI)DINE RING USEFUL IN THE|TREATMENT OF INFECTIOUS DISEASES
  [FR] COMPOSÉS BICYCLIQUES FUSIONNÉS EN 6-6 OU 5-6 COMPRENANT UN CYCLE PYRI(MI)DINE UTILES DANS LE TRAITEMENT DE MALADIES INFECTIEUSES

  摘要：

  The present invention relates to new specific 6-6 or 5-6 fused bicyclic compounds comprising pyrimidine or pyridine useful in the prevention and/or treatment of infectious diseases. In particular, the present invention relates to a compound of formula (I) wherein : Ar1is a (C5-C11)arylene or (C5-C11)heteroarylene group, X is -CH-, -S-, -NR5or -N-, Y is -CH-, -NR5-S- or -NR6-CH2-, T is -CH- and Q is -CH- or T is -N- and Q is -CR10- or -N-, provided that one or two of X, Q and Y comprise a heteroatom, and with the proviso that, at least one of R1, R2, and, if present, R5or R6, contains a group -NH-Alk-NR3R4. The inventors showed that compounds of formula (I) present an activity against both W2 and 3D7 Plasmodium falciparum strains, an activity against T. brucei brucei but also an activity against SARS-CoV-2 virus, and that they are positive for G4 recognition. The invention also relates to the preparation process and to the therapeutic uses of the compounds of formula (I).

  公开号：

  WO2022129376A1
• 作为产物：
  描述：

  3-(二甲氨基)丁腈 在 乙醇 、 sodium 作用下， 生成 N-(3-氨基-1-甲基丙基)-N,N-二甲胺
  参考文献：
  名称：

  Bruylants, Bulletin des Societes Chimiques Belges, 1923, vol. 32, p. 265

  摘要：

  DOI：

文献信息

• [EN] SUBSTITUTED TETRACYCLINE COMPOUNDS<br/>[FR] COMPOSÉS À BASE DE TÉTRACYCLINES SUBSTITUÉES
  申请人：PARATEK PHARM INNC

  公开号：WO2009128913A1

  公开（公告）日：2009-10-22

  The present invention pertains, at least in part, to methods of treating a microorganism-associated infection in a subject comprising administering to said subject an effective amount of a tetracycline compound.

  本发明至少部分涉及治疗宿主微生物相关感染的方法，包括向宿主施用有效量的四环素化合物。
• [EN] MODULATORS OF THE ADENOSINE A2A RECEPTOR<br/>[FR] MODULATEURS DU RÉCEPTEUR A2A DE L'ADÉNOSINE
  申请人：RYVU THERAPEUTICS S A

  公开号：WO2020128036A1

  公开（公告）日：2020-06-25

  The present invention relates to the compounds of formula (I) and salts, stereoisomers, tautomers, isotopologues, or N-oxides thereof. The present invention is further concerned with the use of such a compounds or salt, stereoisomer, tautomer, isotopologues, or N- oxide thereof as modulators of the adenosine A2A receptor in the treatment of cancer and a pharmaceutical composition comprising said compounds.

  本发明涉及式(I)的化合物及其盐、立体异构体、互变异构体、同位素同分异构体或N-氧化物。本发明进一步涉及将这些化合物或盐、立体异构体、互变异构体、同位素同分异构体或N-氧化物用作调节腺苷A2A受体在癌症治疗中的药物，并包括所述化合物的药物组合物。
• [EN] TGFBETAR2 INHIBITOR-LRRC15 ANTIBODY CONJUGATES AND USES THEREOF<br/>[FR] CONJUGUÉS INHIBITEUR DE TGFBETAR2-ANTICORPS ANTI-LRRC15 ET LEURS UTILISATIONS
  申请人：SILVERBACK THERAPEUTICS INC

  公开号：WO2021102332A1

  公开（公告）日：2021-05-27

  Conjugates comprising a TGFβR2 inhibitor and an anti-LRRC15 antibody, compositions comprising the conjugates, and use of the conjugates in the treatment of disease, such as fibrosis and cancer, are disclosed herein. Also disclosed herein are anti-LRRC15 antibodies, including humanized anti-LRRC15 antibodies.

  本文披露了包括TGFβR2抑制剂和抗LRRC15抗体在内的共轭物，包括这些共轭物的组合物，以及在治疗疾病（如纤维化和癌症）中使用这些共轭物的方法。本文还披露了抗LRRC15抗体，包括人源化的抗LRRC15抗体。
• Pyridopyrazines and derivatives thereof as alk and c-Met inhibitors
  申请人：Dorsey D. Bruce

  公开号：US20080032972A1

  公开（公告）日：2008-02-07

  The present invention provides a compound of Formula I or a pharmaceutically acceptable salt form thereof, wherein A, L 1 , R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , and X are as defined herein. The compounds of Formula I have ALK and/or c-Met inhibitory activity, and may be used to treat ALK- or c-Met-mediated disorders or conditions.

  本发明提供了化合物I的结构或其药学上可接受的盐形式，其中A、L1、R1、R2、R3、R4、R5、R6和X的定义如本文所述。化合物I具有ALK和/或c-Met抑制活性，并可用于治疗ALK或c-Met介导的疾病或病症。
• PYRIDOPYRAZINES AND DERIVATIVES THEREOF AS ALK AND c-MET INHIBITORS
  申请人：Dorsey Bruce D.

  公开号：US20100048576A1

  公开（公告）日：2010-02-25

  The present invention provides a compound of Formula I or a pharmaceutically acceptable salt form thereof, wherein A, L 1 , R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , and X are as defined herein. The compounds of Formula I have ALK and/or c-Met inhibitory activity, and may be used to treat ALK- or c-Met-mediated disorders or conditions.

  本发明提供了I式化合物或其药学上可接受的盐形式，其中A、L1、R1、R2、R3、R4、R5、R6和X的定义如本文所述。I式化合物具有ALK和/或c-Met抑制活性，可用于治疗ALK或c-Met介导的疾病或病状。